ARFIP1

ARFIP1 Full Name

ADP-ribosylation factor interacting protein 1

ARFIP1 Introduction

ATF3 (activating transcription factor 3) is a member of the activating transcription factor/cAMP-responsive element-binding protein (ATF/CREB) family of basic leucine zipper (bZIP) transcription factors. The gene is located on chromosome 1q32.3 and encodes a protein of 181 amino acids with a molecular weight of approximately 21 kDa. ATF3 is rapidly and robustly induced by a diverse array of stress signals including endoplasmic reticulum stress, oxidative stress, DNA damage, inflammatory cytokines, growth factor withdrawal, and hypoxia, establishing it as a key immediate-early stress-responsive transcription factor. Unlike most transcription factors that act as constitutive regulators, ATF3 functions as an adaptive regulator that is normally expressed at very low levels in most tissues but is rapidly upregulated in response to cellular stress. Depending on the cellular context and the nature of the stress signal, ATF3 can function as either a transcriptional activator or a repressor by forming homodimers or heterodimers with other bZIP family members including c-JUN, JUNB, JUND, C/EBPδ, and ATF2. ATF3 plays critical roles in regulating cellular metabolism, immune responses, apoptosis, cell cycle progression, and tissue repair, and its dysregulation has been implicated in various human diseases including cancer, inflammatory disorders, cardiovascular disease, diabetes, and neurodegeneration.

Figure 1. Schematic structure of ARFIP1.

Functions in Stress Response and Inflammation
ATF3 is a master regulator of the cellular adaptive response to stress, functioning to restore homeostasis following injury or insult. Upon stress stimulation, ATF3 expression is rapidly induced through multiple signaling pathways including the JNK/p38 MAPK pathway, the ER stress pathway (PERK/eIF2α/ATF4), and the DNA damage pathway (p53). Once induced, ATF3 coordinates a broad transcriptional program that modulates cell cycle progression, apoptosis, DNA repair, metabolism, and inflammation. In the context of inflammation, ATF3 functions as a negative feedback regulator that limits the magnitude and duration of inflammatory responses. ATF3 directly represses the transcription of pro-inflammatory cytokines including TNF-α, IL-6, IL-12, and IL-1β by competing with NF-κB and other transcription factors for promoter binding or by recruiting co-repressors such as HDAC1. ATF3 also regulates the expression of chemokines (CCL2, CCL5, CXCL2), adhesion molecules (ICAM1, VCAM1), and inflammatory enzymes (COX2, iNOS). ATF3 knockout mice exhibit exaggerated inflammatory responses and are more susceptible to endotoxic shock, sepsis, and autoimmune diseases. In the regulation of apoptosis, ATF3 has dual and context-dependent functions. ATF3 promotes apoptosis in some contexts by upregulating pro-apoptotic genes including PUMA, NOXA, BAX, and BIM, while suppressing anti-apoptotic genes such as BCL2 and BCL-XL. In other contexts, particularly following chronic or mild stress, ATF3 promotes cell survival by inducing cytoprotective genes including heat shock proteins, antioxidant enzymes (SOD2, catalase), and DNA repair factors (GADD45, PCNA). This context-dependent switching between pro-apoptotic and pro-survival functions is determined by the nature, intensity, and duration of the stress signal, as well as by the availability of heterodimerization partners.

Regulation and Therapeutic Implications
ATF3 expression is tightly regulated at multiple levels, enabling rapid and dynamic responses to cellular stress. At the transcriptional level, ATF3 is induced by a wide range of transcription factors that respond to specific stress signals. The ATF3 promoter contains binding sites for AP-1, NF-κB, p53, HIF-1α, ATF4, and CREB, allowing integration of diverse stress signals. ATF3 is also a target of negative feedback regulation; ATF3 protein represses its own promoter, limiting the duration of its expression. At the post-transcriptional level, ATF3 mRNA stability is regulated by AU-rich elements in its 3' untranslated region, and several microRNAs including miR-21, miR-200b, and miR-365 target ATF3 mRNA for degradation. At the post-translational level, ATF3 protein stability is regulated by ubiquitination and proteasomal degradation, and its activity is modulated by phosphorylation (by JNK and p38 MAPK) and by acetylation (by p300). Therapeutically, ATF3 is being explored as a target in several diseases. In cancer, strategies to restore ATF3 expression in tumors where it functions as a tumor suppressor (breast, colorectal) using small molecule inducers (e.g., the HDAC inhibitor entinostat) are being explored. In cancers where ATF3 is oncogenic, inhibitors of ATF3 expression or activity (e.g., antisense oligonucleotides, dominant-negative peptides) are in preclinical development.

Alternate Names for ARFIP1

ARFIP1; ADP-ribosylation factor interacting protein 1; arfaptin-1; arfaptin 1; HSU52521; ADP-ribosylation factor-interacting protein 1; MGC117369;